Mylan (MYL) and Pfizer's (PFE) Upjohn to Combine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/15/2026
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Trump slams Anthropic CEO over AI slowdown call
- Oil prices soar over 4% to 16-week high after Saudi strikes
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Citi sees memory market undersupply worsening through 2031
- Global AI stocks fall as industry chiefs call for slowing development
- Enova drops bid to acquire Grasshopper Bancorp, reaffirms guidance
- Baldwin Group to go private in $7.7 billion deal with Sequence and Dell family office
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
UPDATE: Pfizer (PFE) Tops Q2 EPS by 5c, Revenues Miss; Lowers FY19 EPS/Revenue Guidance
July 29, 2019 6:51 AM EDT(Updated - July 29, 2019 6:54 AM EDT)
Pfizer (NYSE: PFE) reported Q2 EPS of $0.80, $0.05 better than the analyst estimate of $0.75. Revenue for the quarter came in at $13.26 billion versus the consensus estimate of $13.4 billion.
Second-Quarter 2019 Revenues of $13.3 Billion, Reflecting 2% Operational Growth Driven by 6% Operational Growth from Pfizer Biopharmaceuticals GroupSecond-Quarter 2019 Reported Diluted EPS(1) of $0.89, Adjusted Diluted EPS(2) of $0.80Updated 2019 Financial Guidance Primarily to Reflect the Anticipated August 1, 2019 Formation of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc(3) and the Anticipated Near-Term Completion of the Array BioPharma Inc. AcquisitionAnnounces Reverse Morris Trust... More